Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF)

51.60 0.00 (0.00%) 市場開市。 截至 11:25AM EDT。

Recordati Industria Chimica e Farmaceutica S.p.A.

Via Matteo Civitali,1
Milan, MI 20148
Italy
39 02 487871
https://www.recordati.com

版塊: Healthcare
行業: Drug Manufacturers - General
全職員工: 4,455

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Robert Koremans M.D.	CEO & Director	1.94M	無	1962
Mr. Luigi Felice La Corte	Group CFO & Executive Director	1.02M	無	1969
Ms. Cathrin Petty	Executive Director	無	無	1973
Mr. Giampiero Mazza	Executive Director	無	無	1969
Mr. Giorgio De Palma	Executive Director	無	無	1974
Ms. Eugenia Litz	VP & Head of Investor Relations	無	無	無
Ms. Bibianne Bon	Group Chief Legal Officer	無	無	無
Ms. Laura Conti	Group Communications Director	無	無	無
Mr. Gabriele Finzi	Executive VP of Corporate Development, Licensing & Innovation	無	無	無
Ms. Alessandra Abate	Group Chief People & Culture Officer	無	無	無

截止 2022年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing's syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis. The company also develops CARBAGLU for hyperammonemia due to NAGS deficiency; QARZIBA, an apeiron for the treatment of high-risk neuroblastoma patients with a partial response at the chemotherapeutical through myeloablative therapy and stem cell transplantation, and relapsed or refractory neuroblastoma. In addition, it offers SYLVANT for the treatment of idiopathic multicentric Castleman diseases; REAGILA for Schizophrenia; and ELIGARD for hormone-dependent prostate cancer, as well as CAPHOSOL, a medical device for treatment of oral mucositis due to chemo and radiation therapy. The company was founded in 1926 and is headquartered in Milan, Italy. Recordati Industria Chimica e Farmaceutica S.p.A. operates as a subsidiary of Rossini S.à R.L.

公司管治

截至 2024年4月29日 止，Recordati Industria Chimica e Farmaceutica S.p.A. 的 ISS 管治質素評分為 3。 Pillar 分數正在審核中：3；董事會：7；股東權利：3；現金賠償：2。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。